Table 1 Characteristics of patients

Age (SD) (years)

75.7 ± 7.1

78.2 ± 6.2

0.02

Sex (Men/Women)

60 (87.0%) /9 (13.0%)

60 (82.2%) /13 (17.8%)

0.43

 Hypertension

41 (59.4%)

53 (72.6%)

0.10

 Diabetes mellitus

17 (24.6%)

26 (35.6%)

0.15

 Hyperlipidemia

30 (43.5%)

35 (47.9%)

0.59

 Ischemic heart disease

28 (40.6%)

29 (39.7%)

0.92

 Cerebrovascular disease

28 (40.6%)

26 (35.6%)

0.54

 Renal disease (eGFR < 30 mL/min/1.73m²)

1 (1.4%)

1 (1.4%)

0.97

Antithrombotic agent

0.50

 Single antiplatelets

32 (46.4%)

37 (50.7%)

 Aspirin

15

20

 Cilostazol

6

5

 Thienopyridine

11

12

 Single anticoagulants

16 (23.2%)

20 (27.4%)

 Warfarin

7

7

 DOACs

9

13

 Multiple therapy

21 (30.4%)

16 (21.9%)

 Anticoagulant + antiplatelet

9

7

 DAPT

10

8

 Triplet therapy

2

1

Interruption of antithrombotic agents

55 (79.7%)

41 (56.1%)

< 0.05

 Heparin replacement

12

0

 Aspirin or cilostazol replacement

9

10

Acid blocker

< 0.05

 Esomeprazole

40 (58.0%)

1 (1.4%)

 Vonoprazan

29 (42.0%)

72 (98.6%)

Multiple lesions

11 (15.9%)

14 (19.1%)

0.61